Turku, Finland, May 23, 2025 – Abomics is pleased to share updates to its leadership and team structure as the company continues to grow and strengthen its position in the field of precision medicine.
Henriikka Halinen has been appointed Chief Commercial Officer at Abomics. Henriikka brings more than 20 years of experience in health technology, with a strong background in strategic business development, commercial leadership, and international market expansion. She joined Abomics in April from Philips, and her proven track record in driving growth and fostering innovation will be instrumental in advancing Abomics’ mission to deliver personalized healthcare solutions. Her leadership will play a key role in guiding the company’s continued evolution in the dynamic field of precision medicine.
Phd, Justyna Ulanska-Poutanen has joined Abomics as Business Development Manager. Justyna came on board in early April from Blueprint Genetics, where she most recently served as a Product Manager. She previously held global sales roles focused on rare disease diagnostics. With a strong foundation in molecular medicine and extensive experience in international sales and business development, Justyna brings a unique blend of scientific and commercial expertise. Her global perspective will support Abomics in building strategic partnerships and expanding its international presence in personalized healthcare.
Sami Miettinen, CEO of Abomics, and Dr. Jari Forsström, Chief Medical Officer and Founder, commented:
“As Abomics continues to grow, we consistently assess the capabilities needed to best serve our customers and partners. These new appointments enhance our team’s strength and align with the momentum we’re building for future growth.”
About Abomics
Abomics collaborates with clinical laboratories, clinical research organizations, electronic health record (EHR) providers, genetics companies, and biobanks to deliver pharmacogenetic interpretation services and personalized pharmacogenetic reports. These tools help physicians select the most appropriate medication and dosage based on a patient’s genetic profile.
Abomics also develops medical and pharmaceutical databases that support clinicians in making informed prescribing decisions. In early 2025, Abomics completed its merger with Multirec, a company with over 20 years of experience in providing drug databases and clinical decision support for electronic health records. Multirec’s strong reputation and long-standing partnerships with leading EHR vendors enhance Abomics’ ability to integrate pharmacogenetics into routine clinical workflows in a user-friendly and effective way.
